• Most Popular
  • Most Shared

Antigenics cancer vaccine study shows mixed results

Wed Feb 20, 2008 7:45am EST

Stocks

   

Feb 20 (Reuters) - Antigenics Inc (AGEN.O) said a late-stage trial of its cancer vaccine, Oncophage, in the treatment of metastatic melanoma, a serious form of skin cancer, did not meet its primary goal of overall survival.

Stocks

The biotechnology company said patients in the Oncophage arm fared similarly to those in the physician's choice arm in terms of overall survival.

However, the study showed that patients receiving at least 10 injections of Oncophage had improved median survival of about 3.7 months, the company added. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Deepak Kannan)

Stocks


More from Reuters

Photo

New security restrictions could hurt airlines

NEW YORK (Reuters) - Tighter security measures at U.S. airports following an attempt to blow up a Detroit-bound jet could dampen enthusiasm for air travel, hurting the airline industry just as it seemed poised to recover from a period of bruising losses, some industry experts say.

» More Top News
A Delta Airbus 330 airliner sits on a runway at Detroit Metropolitan Airport in Romulus, Michigan in this video grab made December 25, 2009. Credit: REUTERS/WDIV TV/Handout

The battle in mid-air

The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers.  Full Article 

U.S.
A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
Political Risk in 2010:

Don't say we didn't warn you

With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

Global Markets